Share of the world´s population fully vaccinated against Covid-19
Proporción de la población con vacunación completa contra Covid-19 a nivel mundial
Article Sidebar
PDF (Español (España))
FLIP
HTML (Español (España))
EPUB (Español (España))
Main Article Content
Abstract
Introduction: despite the celebrated development, licensure and distribution of effective COVID-19 vaccines, the number of recently reported cases and deaths continued to rise globally up to the Northern Hemisphere summer of 2021. Objective: to show the countries with the highest percentage of absolute change of people vaccinated against COVID-19 between December 13 2020 and January 6 2022. Methodology: a cross-sectional study was conducted for this research, based on the Our World in Data web page COVID-19 vaccination data. Results: it was determined that the countries with the highest percentage of absolute change of vaccinated people were: Gibraltar (117.73), Portugal (89.65), United Arab Emirates (88.97), Brunei (87.27), Singapore (87), and Chile (86.35). Conclusion: vaccine delivery systems and infrastructure require to be established to ensure COVID-19 vaccines access to priority target groups around the world.
Keywords:
Downloads
Article Details
References
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4 DOI: https://doi.org/10.1016/S0140-6736(20)31604-4
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577 DOI: https://doi.org/10.1056/NEJMoa2034577
Coronavirus Resource Center. Covid-19 data [Internet]. Johns Hopkins University & Medicine; 2022 [cited 2021 noviembre 3]; Available from: https://coronavirus.jhu.edu/
Dhar MS, Marwal R, Radhakrishnan VS, Ponnusamy K, Jolly B, et al. Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. Science. 2021;374(6570):995-999. https://doi.org/10.1101/2021.06.02.21258076 DOI: https://doi.org/10.1101/2021.06.02.21258076
Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina Esteban, et al. Coronavirus (COVID-19) Vaccinations [Internet]. Our World in Data; 2020 [cited 2021 noviembre 3]; Available from: https://ourworldindata.org/covid-vaccinations
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, et al. COVE Study Group. Efficacy and safety of the mRNA1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16. doi: 10.1056/NEJMoa2035389 DOI: https://doi.org/10.1056/NEJMoa2035389
Voysey M, Clemens SAC, Madhi SA, et al Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1 DOI: https://doi.org/10.1016/S0140-6736(20)32661-1
Sadoff J, Gray G, Vandebosch A, Cárdenas V, et al. Safety and efficacy of singledose Ad26.COV2. S vaccine against covid-19. N Engl J Med. 2021;384(23):2187-2201. doi: 10.1056/NEJMoa2101544 DOI: https://doi.org/10.1056/NEJMoa2101544
Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness, and escape. Nat Rev Immunol 2021;21(10):626-636. doi: 10.1038/s41577-021-00592-1. DOI: https://doi.org/10.1038/s41577-021-00592-1
Cevik M, Grubaugh ND, Iwasaki A, Openshaw P. COVID-19 vaccines: Keeping pace with SARSCoV-2 variants. Cell 2021;184(20):5077-5081. doi: 10.1016/j.cell.2021.09.010 DOI: https://doi.org/10.1016/j.cell.2021.09.010
Richterman A, Meyerowitz EA, Cevik M. Indirect protection by reducing transmission: ending the pandemic with SARS-CoV-2 vaccination. Open Forum Infect Dis. 2021;9(2):ofab259. doi: 10.1093/ofid/ofab259 DOI: https://doi.org/10.1093/ofid/ofab259
Díaz Pinzón, J. E. (2020). Descripción estadística del COVID- 19 según el grupo etario en Colombia. Repert Med Cir. 2020;29(Núm. Supl.1):79–85. https://doi.org/10.31260/RepertMedCir.01217372.1098 DOI: https://doi.org/10.31260/RepertMedCir.01217372.1098
Díaz Pinzón JE. Continuidad con los procesos pedagógicos de los estudiantes durante la pandemia ocasionada por el COVID-19. Repert Med Cir. 2020;29(Núm. Supl.1):108–112. https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/1128
Díaz Pinzón JE. Positividad y proporción para muestras por COVID-19 en Colombia. Repert Med Cir. 2020;29(Núm. Supl.1):127-130. https://doi.org/10.31260/RepertMedCir.01217372.1134 DOI: https://doi.org/10.31260/RepertMedCir.01217372.1134
Our World in Data COVID-19. Estadística e Investigación: Vacunas contra el Coronavirus (COVID-19). [Internet]. 2022 [citado 2022 enero]; Disponible en: https://ourworldindata.org/covid-vaccinations
Organización Panamericana de la Salud (OPS). Introducción de la vacuna contra la COVID-19: Orientaciones para determinar los grupos prioritarios y elaborar la micro planificación [Internet]. 2021 [citado 2022 enero]; Disponible en: https://iris.paho.org/bitstream/handle/10665.2/53250/OPSFPLIMCOVID-19210008_por.pdf?sequence=5